Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 Plus BP102 in Advanced Non-Squamous NSCLC
NCT04974957Phase 2Unknown
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04974957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974957.